These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 20061930)
1. Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. Cortinovis M; Gotti E; Remuzzi G; Perico N; Cattaneo D; Baldelli S Transplantation; 2010 Jan; 89(1):126-7. PubMed ID: 20061930 [No Abstract] [Full Text] [Related]
2. Use of sirolimus in solid organ transplantation. Augustine JJ; Bodziak KA; Hricik DE Drugs; 2007; 67(3):369-91. PubMed ID: 17335296 [TBL] [Abstract][Full Text] [Related]
3. Acute drug toxicity related to drinking herbal tea in a kidney transplant recipient. Kwan LP; Mok MM; Ma MK; Lam MF Ren Fail; 2014 Mar; 36(2):309-12. PubMed ID: 24180243 [TBL] [Abstract][Full Text] [Related]
4. Reduced exposure to calcineurin inhibitors in renal transplantation. Guba M; Jauch KW N Engl J Med; 2008 Jun; 358(23):2518; author reply 2519-20. PubMed ID: 18525054 [No Abstract] [Full Text] [Related]
5. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522 [TBL] [Abstract][Full Text] [Related]
12. Considerations in sirolimus use in the early and late post-transplant periods. Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662 [TBL] [Abstract][Full Text] [Related]
13. Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients. Bandur S; Petrasek J; Hribova P; Novotna E; Brabcova I; Viklicky O Transplantation; 2011 Jan; 91(1):e1-2. PubMed ID: 21441846 [No Abstract] [Full Text] [Related]
14. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289 [TBL] [Abstract][Full Text] [Related]
15. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia. Med Lett Drugs Ther; 2005 Nov; 47(1221):91. PubMed ID: 16267495 [No Abstract] [Full Text] [Related]
16. Sirolimus, the first mTOR inhibitor. Sánchez-Plumed JA; González Molina M; Alonso A; Arias M Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632 [No Abstract] [Full Text] [Related]
17. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806 [TBL] [Abstract][Full Text] [Related]
18. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598 [TBL] [Abstract][Full Text] [Related]
19. The pros and the cons of mTOR inhibitors in kidney transplantation. Ponticelli C Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908 [TBL] [Abstract][Full Text] [Related]
20. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Gabardi S; Baroletti SA Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]